Hamlet BioPharma Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Petter Lindqvist
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO
Petter Lindqvist
1.1yrs
Tenure
Mr. Petter Segelman Lindqvist serves as Chief Executive Officer of Isofol Medical AB (publ) since January 09, 2024. He is Chief Executive Officer of Hamlet BioPharma AB (publ) (formerly known as Hamlet Pha...